Please login to the form below

Not currently logged in
Email:
Password:

Ashfield Engage taps Keith Buckby as UK business development director

Buckby returns to Ashfield Engage after having previously worked for Ashfield for over 11 years

Ashfield Engage has announced the appointment of Keith Buckby (pictured above) as UK business development director.

Buckby returns to Ashfield Engage – part of UDG Healthcare – after having previously worked for Ashfield for over 11 years across a number of operational roles.

In addition, he also led the recruitment team and commercial operations functions before leaving the company in 2018.

Prior to returning to Ashfield, Buckby completed a two-year stint at IQVIA, where he most recently held the role of business development director.

“I’m delighted to welcome Keith back to Ashfield Engage and I know he shares the same values and high standards in exceeding our clients’ expectations,” said Mick O’Leary, regional president, North Europe.

“His industry expertise, plus his broad experience across our service portfolio will be invaluable as he helps guide the future direction for the transforming UK business,” he added.

“I am really thrilled to be re-joining the team at such an exciting time. People are my passion and I know that human, personal connections are at the heart of Ashfield Engage’s services – I’m looking forward to sharing this passion with our clients as part of my new chapter at Ashfield,” commented Buckby.

Article by
Lucy Parsons

11th March 2021

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...